Immunotherapy for renal cell carcinoma: the era of interleukin-2-based treatment.
Taneja
S S
SS
Department of Surgery, University of California, Los Angeles School of Medicine, USA.
Pierce
W
W
Figlin
R
R
Belldegrun
A
A
D000465:Algorithms; D002199:Capillary Permeability / Q000187:drug effects; D002292:Carcinoma, Renal Cell / Q000556:secondary / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D016219:Immunotherapy, Adoptive; D016898:Interferon-alpha / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use*; D007674:Kidney Diseases / Q000139:chemically induced; D007680:Kidney Neoplasms / Q000473:pathology / Q000628:therapy*; D014652:Vascular Diseases / Q000139:chemically induced
D016898:Interferon-alpha; D007376:Interleukin-2